CN111466572A - 一种具有调节肠道功能的益生菌粉及其制备方法 - Google Patents
一种具有调节肠道功能的益生菌粉及其制备方法 Download PDFInfo
- Publication number
- CN111466572A CN111466572A CN201910486048.0A CN201910486048A CN111466572A CN 111466572 A CN111466572 A CN 111466572A CN 201910486048 A CN201910486048 A CN 201910486048A CN 111466572 A CN111466572 A CN 111466572A
- Authority
- CN
- China
- Prior art keywords
- powder
- parts
- probiotic
- lactobacillus acidophilus
- bifidobacterium lactis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 72
- 239000006041 probiotic Substances 0.000 title claims abstract description 49
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 49
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 45
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 35
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 38
- 244000068988 Glycine max Species 0.000 claims abstract description 35
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 32
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 32
- 244000116699 Lactobacillus acidophilus NCFM Species 0.000 claims abstract description 30
- 235000009195 Lactobacillus acidophilus NCFM Nutrition 0.000 claims abstract description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 150000004676 glycans Chemical class 0.000 claims abstract description 19
- 229920001184 polypeptide Polymers 0.000 claims abstract description 19
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 19
- 239000005017 polysaccharide Substances 0.000 claims abstract description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 19
- 229920001353 Dextrin Polymers 0.000 claims abstract description 18
- 239000004375 Dextrin Substances 0.000 claims abstract description 18
- 235000019425 dextrin Nutrition 0.000 claims abstract description 18
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims abstract description 18
- 239000000832 lactitol Substances 0.000 claims abstract description 18
- 229960003451 lactitol Drugs 0.000 claims abstract description 18
- 235000010448 lactitol Nutrition 0.000 claims abstract description 18
- 230000006870 function Effects 0.000 claims abstract description 17
- 229930091371 Fructose Natural products 0.000 claims abstract description 16
- 239000005715 Fructose Substances 0.000 claims abstract description 16
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 16
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 16
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims abstract description 16
- 239000001259 polydextrose Substances 0.000 claims abstract description 16
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 16
- 229940035035 polydextrose Drugs 0.000 claims abstract description 16
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 15
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 14
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 14
- 239000002131 composite material Substances 0.000 claims abstract description 9
- 239000000126 substance Substances 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 3
- 230000003871 intestinal function Effects 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 abstract description 14
- 230000036039 immunity Effects 0.000 abstract description 10
- 230000002708 enhancing effect Effects 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 19
- 230000009286 beneficial effect Effects 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 235000020824 obesity Nutrition 0.000 description 5
- 150000004666 short chain fatty acids Chemical class 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 201000010538 Lactose Intolerance Diseases 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008855 peristalsis Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010062877 Bacteriocins Proteins 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 244000000074 intestinal pathogen Species 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种具有调节肠道功能的益生菌粉及其制备方法,属于益生菌食品技术领域。该益生菌粉由嗜酸乳杆菌NCFM菌粉和乳双歧杆菌HN019菌粉,复合益生元,二氧化硅和果糖制备而成;其中复合益生元由乳糖醇,低聚异麦芽糖,抗性糊精,聚葡萄糖,大豆多糖和大豆多肽组成。本发明还提供了该益生菌粉的制备方法。本发明益生菌粉具有缓解便秘、降低体重、增强免疫力以及调节肠道的功能。
Description
技术领域
本发明涉及一种具有调节肠道功能的益生菌粉及其制备方法,属于益生菌食品技术领域。
背景技术
肠道是人体内最大的微生物环境,微生物种类多达400多种,数量高达10万亿。机体健康与有益菌的数量有着密切的联系,其肠道微生态是否平衡直接影响着人体的健康与寿命,消化道菌群失调会引起一系列疾病,例如糖尿病、便秘以及肥胖等。
随着社会的进步和生活水平的提高,人们摄入的食物越来越精细,出行的交通工具越来越便捷高效,运动量逐渐减少,使得便秘、肥胖等疾病成为一种常见的疾病。同时现代社会的生活节奏越来越快,压力过大、长时间加班熬夜以及情绪起伏不定等多种原因,常会导致胃肠功能紊乱,导致肠道内有益菌数量减少,而有害菌大量增殖的现象,在肠道内产生腐败产物、细菌素等有害物质,从而导致肥胖、便秘等问题随之而来。肠道内的益生菌数量会随着年龄的增长而逐渐减少,有害菌的数目上升,使得糖尿病、便秘问题在中老年人群中尤为常见。此外,我国部分城市的健康儿童中患有乳糖不耐症的几率较高,且乳糖酶的活性随着年龄的增长而逐渐减低,直至消失,因此在成年人中也常出现乳糖不耐症。在乳糖不耐症人群的肠道中,无法消化的乳糖会被细菌酵解成乳酸、氢气和二氧化碳等代谢产物,刺激肠壁、增加肠道蠕动而出现胀气、腹泻以及腹痛等症状。基于此,可以看出便秘、肥胖以及糖尿病等疾病的发生与人体肠道内的菌群有着密切的关联,肠道内的益生菌数目在一定程度上能够衡量机体消化道的健康。
益生菌是一类对宿主有益的活性微生物,是定植于人体肠道、生殖系统内,能够产生确切健康功效从而改善宿主微生态平衡、发挥有益作用的活性有益微生物的总称。当人体肠道内的益生菌数目达到一定水平时,其会在肠道内粘附定植,同时产生乙酸、乳酸、细菌素等物质降低肠道的pH值,有效地抑制肠道内有害菌的生长。因此,近些年来,益生菌类的产品受到消费者的广泛青睐,但大部分益生菌类产品在人体服用后,经过胃酸、胆汁等极端环境才能到达肠道发挥作用,此时益生菌的数量及活力大大降低,效果明显下降。因而,如何有效地提高益生菌类产品的作用效果显得尤为重要。
目前,市场上存在较多的益生菌类产品,这些产品大多是由一种或多种益生菌、益生元以及其他各种具有生物活性的物质,结合一些常见的制备技术制得,原料配比较单一,且益生菌未经过任何处理,产品应用效果较差。
发明内容
本发明提供了一种具有调节肠道功能的益生菌粉及其制备方法,该益生菌粉具有更好的缓解便秘、降低体重、增强免疫力以及调节肠道的效果,采用的技术方案如下:
本发明的目的在于提供一种具有调节肠道功能的益生菌粉,该益生菌粉由嗜酸乳杆菌NCFM菌粉和乳双歧杆菌HN019菌粉,复合益生元,二氧化硅和果糖制备而成;其中复合益生元由乳糖醇,低聚异麦芽糖,抗性糊精,聚葡萄糖,大豆多糖和大豆多肽组成;各原料的重量份数如下:嗜酸乳杆菌NCFM菌粉5份~10份,乳双歧杆菌HN019菌粉5份~10份,乳糖醇1份~5份,低聚异麦芽糖1份~5份,抗性糊精1份~5份,聚葡萄糖1份~5份,大豆多糖1份~2份,大豆多肽0.1份~0.5份,二氧化硅0.2份~0.8份,果糖0.1份~0.4份。
优选地,各原料的重量份数如下:嗜酸乳杆菌NCFM菌粉7.5份,乳双歧杆菌HN019菌粉7.5份,乳糖醇3.5份,低聚异麦芽糖2份,抗性糊精3份,聚葡萄糖2.5份,大豆多糖1.3份,大豆多肽0.2份,二氧化硅0.5份,果糖0.3份。
优选地,所述嗜酸乳杆菌NCFM菌粉的活菌数在100亿以上;所述乳双歧杆菌HN019菌粉的活菌数在100亿以上。
本发明提供了一种上述益生菌粉的制备方法,该制备方法是将乳糖醇、低聚异麦芽糖、抗性糊精、聚葡萄糖、大豆多糖和大豆多肽按比例混合均匀,过筛后取筛下物质称重,然后将其与嗜酸乳杆菌NCFM菌粉、乳双歧杆菌HN019菌粉、二氧化硅和果糖按比例混合均匀。
优选地,所述混匀是在环境温度为20℃、环境湿度为40%的条件下进行的。
本发明中的嗜酸乳杆菌NCFM菌粉是指将嗜酸乳杆菌NCFM经过冻干包埋处理后的冻干粉,可以通过商业途径购买获得。本发明中的乳双歧杆菌HN019菌粉是指将嗜酸乳杆菌NCFM经过冻干包埋处理后的冻干粉,可以通过商业途径购买获得。
本发明所采用的原料:
乳双歧杆菌HN019:益生菌与肠道黏膜间存在相互作用,乳双歧杆菌HN019对肠道免疫系统有着十分重要的影响,不仅可以促进免疫调节,而且可以抵御肠道病原体,限制了病原体侵占肠道的能力。研究表明,健康成人每日服用乳双歧杆菌HN019可减少结肠运输时间以及改善功能性胃肠道症状,且其体外实验中耐受胆汁和低PH值的能力非常突出。此外,乳双歧杆菌HN019还可以大量地粘附在不同类型的人工培养的肠道上皮黏膜上,验证了该菌株能够在通过胃肠道系统过程中始终保持活性。
嗜酸乳杆菌NCFM:大量成功的消化系统健康临床研究证明,嗜酸乳杆菌NCFM是一株可有效支持肠道健康的益生菌。其能产生短链脂肪酸,缩短结肠转运时间,从而减少腹胀等其它不适症状,还有促进肠道蠕动的作用,从而缓解便秘等症状。
乳糖醇:乳糖醇基本不会被小肠吸收而直接到达大肠,在肠道中被微生物发酵生成短链脂肪酸,从而降低肠道酸度,刺激肠道蠕动。乳糖醇是高倍的益生元,乳酸双歧杆菌和嗜酸乳杆菌均能较好地利用乳糖醇发酵增殖。
低聚异麦芽糖:低聚异麦芽糖能被发酵产生短链脂肪酸而降低肠道的pH值,进而抑制肠道病原菌微生物,增殖双歧杆菌,以及提高矿物质的可利用性。同时具有膳食纤维的功能,可增加大便持水性和容量,从而可缓解便秘;可吸附肠道中阴离子和胆汁酸而有效地降低血脂和胆固醇;还能诱导有利于宿主健康的肠道局部免疫或全身免疫反应,具有增强免疫力的作用。
聚葡萄糖:聚葡萄糖除具有水溶性膳食纤维所特有的明显增加粪便体积、增强通便、降低患肠道癌的风险等作用外,还具有水溶性膳食纤维所不具备或不明显的功能,如结合清除体内的胆酸、明显降低血清胆固醇、易引致饱腹感以及能明显降低饭后血糖水平等。
抗性糊精:抗性糊精不被胃肠吸收,可直接到达大肠被人体肠道中的有益微生物利用,刺激益生菌生长、繁殖,抑制肠道有害微生物,为人体提供有益的调节物质,提高人体的免疫系统和肠道功能。同时,抗性糊精经部分肠道有益菌发酵产生短链脂肪酸,产酸量较同等膳食纤维多,这些短链脂肪酸能阻止癌细胞的生长与繁殖,有效预防直肠癌。另外,抗性糊精吸水膨胀能增加粪便体积,促进肠道蠕动,对于便秘、痔疮、结肠癌等疾病均有良好的预防效果。
二氧化硅:二氧化硅有大的比表面积,使其能在粉末物质的颗粒之间起到间隔剂的作用。同时促进了粉末物质的自由流动,吸湿性能极大,也增强了抗结块作用和吸附作用。
果糖:果糖主要产自天然的水果和谷物之中,是一种全天然、甜味浓郁的新糖类,不易导致高血糖,不易产生脂肪堆积而发胖,更不会产生龋齿,而被广泛应用到食品行业。
本发明有益效果:
本发明提供了一种具有调节肠道功能的益生菌粉,该益生菌粉采用了由六种益生元复合而成的复合益生元与嗜酸乳杆菌或乳双歧杆菌进行搭配,得到一种成本低、口感较好、产品稳定、效果显著、可被消费者广泛接受的具有调节肠道功能的益生菌粉,有效地提高了益生菌的功效,使到达肠道内的益生菌数目增多,活力增强,耐酸耐胆汁的能力显著提升,食用后具有缓解便秘、降低体重、增强免疫力以及调节肠道的功效,且作用效果明显。
本发明通过将乳糖醇、抗性糊精、聚葡萄糖、低聚异麦芽糖、大豆多糖、大豆多肽6种益生元复配,使得在不提高益生元用量甚至减少益生元用量的基础上,依旧能够达到较好的甚至更好地调节肠道。
本发明益生菌粉中添加大豆多糖有利于乳杆菌和双歧杆菌的增殖;添加大豆多肽能够促进嗜酸乳杆菌NCFM菌粉和乳双歧杆菌HN019菌粉的生长和繁殖,具有促进微生物生长发育和新陈代谢的作用,并且能够有效降低肠道中大肠杆菌数量,提高嗜酸乳杆菌NCFM和乳双歧杆菌HN019的数量,进而使得益生菌粉能够发挥更好的缓解便秘、降低体重、增强免疫力以及调节肠道的效果。
附图说明
图1为未添加大豆多肽和添加1%大豆多肽后嗜酸乳杆菌NCFM和乳双歧杆菌HN019在MRS液体培养基中的生长曲线图。
图2为未添加大豆多糖和添加5%大豆多糖后嗜酸乳杆菌NCFM和乳双歧杆菌HN019在MRS液体培养基中的生长曲线图。
具体实施方式
下面结合具体实施例对本发明做进一步说明,但本发明不受实施例的限制。
以下实施例中以嗜酸乳杆菌NCFM菌粉和乳双歧杆菌HN019菌粉均购自商业途径,嗜酸乳杆菌NCFM菌粉和乳双歧杆菌HN019菌粉的活菌数均在100亿以上。
实施例1:
本实施例提供了一种具有调节肠道功能的益生菌粉,该配方中的各原料的重量份数如下:嗜酸乳杆菌NCFM菌粉5份,乳双歧杆菌HN019菌粉5份,乳糖醇1份,低聚异麦芽糖1份,抗性糊精1份,聚葡萄糖1份,大豆多糖1份,大豆多肽0.1份,二氧化硅0.2份,果糖0.1份;每份取100kg。
该益生菌粉的制备方法为:首先将益生菌与海藻糖将乳糖醇、低聚异麦芽糖、抗性糊精、聚葡萄糖、大豆多糖和大豆多肽按比例混合均匀,过筛后取筛下物质称重,然后将其与冻干包埋的嗜酸乳杆菌NCFM菌粉和、乳双歧杆菌HN019菌粉进行混合后冻干,最后将包埋后冻干的菌粉与、二氧化硅和果糖按比例混合均匀。
本实施例制备的菌粉为干燥粉末状,其中活菌数达到100亿以上。
将本实施例制备的益生菌粉包装成规格为250g(2.5g*100)的产品。
该益生菌粉的食用方法:服用时用适量温水冲服,每次一袋,每日两次。
实施例2
本实施例与实施例1的区别在于:该配方中各原料的重量份数如下:嗜酸乳杆菌NCFM菌粉10份,乳双歧杆菌HN019菌粉10份,乳糖醇5份,低聚异麦芽糖5份,抗性糊精5份,聚葡萄糖5份,大豆多糖2份,大豆多肽0.5份,二氧化硅0.8份,果糖0.4份;每份取100kg。
实施例3
本实施例与实施例1的区别在于:该配方中各原料的重量份数如下:嗜酸乳杆菌NCFM菌粉7.5份,乳双歧杆菌HN019菌粉7.5份,乳糖醇3.5份,低聚异麦芽糖2份,抗性糊精3份,聚葡萄糖2.5份,大豆多糖1.3份,大豆多肽0.2份,二氧化硅0.5份,果糖0.3份;每份取100kg。
为说明本发明益生菌粉所能够获得的效果进行了如下实验:
1、考察缓解便秘、降低体重、增强免疫力以及调节肠道的效果
将本发明的实施例3中的益生菌粉分装成2.5g/袋,得到若干袋,选取1500名志愿者食用本发明的产品,随机对其身体状况进行观察检测,年龄组分为18~25岁的50名,26~45岁的50名,46~65岁的50名。通过口服的方式服用,每日两次,每次一袋,温水冲调,搅拌均匀后即可服用,检测连续服用30天、60天、90天后的效果,主要检测受试者的排便是否变规律、免疫力是否提高、消化吸收是否变好以及体重是否下降,监测结果如表1。
表1受试者服用益生菌粉后肠道效果变化表
从表1中可以看出,受试者连续服用本发明产品90天后,排便变规律、免疫力提高、消化吸收变好以及体重明显下降。充分说明本发明将包埋冻干后的益生菌与复合益生元结合使用,能够发挥更好的作用,从而达到缓解便秘、降低体重、增强免疫力以及调节肠道的功能。
2、为考察大豆多肽和大豆多糖的效果,进行了如下实验:
在未添加和添加1%大豆多肽的培养基中,嗜酸乳杆菌NCFM和乳双歧杆菌HN019的生长情况如图1所示。从图中可以看出大豆多肽具有显著促进嗜酸乳杆菌NCFM和乳双歧杆菌HN019生长的效果。
在未添加大豆多糖和添加5%大豆多糖的肉汤中,嗜酸乳杆菌NCFM和乳双歧杆菌HN019的生长情况如图2所示。从图中可以看出大豆多糖具有显著促进嗜酸乳杆菌NCFM和乳双歧杆菌HN019生长的效果。
虽然本发明已以较佳的实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可以做各种改动和修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
Claims (5)
1.一种具有调节肠道功能的益生菌粉,其特征在于,所述益生菌粉由嗜酸乳杆菌NCFM菌粉和乳双歧杆菌HN019菌粉,复合益生元,二氧化硅和果糖制备而成;所述复合益生元由乳糖醇,低聚异麦芽糖,抗性糊精,聚葡萄糖,大豆多糖和大豆多肽组成;各原料的重量份数如下:嗜酸乳杆菌NCFM菌粉5份~10份,乳双歧杆菌HN019菌粉5份~10份,乳糖醇1份~5份,低聚异麦芽糖1份~5份,抗性糊精1份~5份,聚葡萄糖1份~5份,大豆多糖1份~2份,大豆多肽0.1份~0.5份,二氧化硅0.2份~0.8份,果糖0.1份~0.4份。
2.根据权利要求1所述的具有调节肠道功能的益生菌粉,其特征在于,各原料的重量份数如下:嗜酸乳杆菌NCFM菌粉7.5份,乳双歧杆菌HN019菌粉7.5份,乳糖醇3.5份,低聚异麦芽糖2份,抗性糊精3份,聚葡萄糖2.5份,大豆多糖1.3份,大豆多肽0.2份,二氧化硅0.5份,果糖0.3份。
3.根据权利要求1或2所述的具有调节肠道功能的益生菌粉,其特征在于,所述嗜酸乳杆菌NCFM菌粉的活菌数在100亿以上;所述乳双歧杆菌HN019菌粉的活菌数在100亿以上。
4.一种权利要求1所述益生菌粉的制备方法,其特征在于,将乳糖醇、低聚异麦芽糖、抗性糊精、聚葡萄糖、大豆多糖和大豆多肽按比例混合均匀,过筛后取筛下物质称重,然后将其与嗜酸乳杆菌NCFM菌粉、乳双歧杆菌HN019菌粉、二氧化硅和果糖按比例混合均匀。
5.根据权利要求4所述的制备方法,其特征在于,所述混匀是在环境温度为20℃、环境湿度为40%的条件下进行的。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910486048.0A CN111466572A (zh) | 2019-06-05 | 2019-06-05 | 一种具有调节肠道功能的益生菌粉及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910486048.0A CN111466572A (zh) | 2019-06-05 | 2019-06-05 | 一种具有调节肠道功能的益生菌粉及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111466572A true CN111466572A (zh) | 2020-07-31 |
Family
ID=71744899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910486048.0A Pending CN111466572A (zh) | 2019-06-05 | 2019-06-05 | 一种具有调节肠道功能的益生菌粉及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111466572A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112006104A (zh) * | 2020-09-07 | 2020-12-01 | 内蒙古百瑞食品科技有限责任公司 | 一种轻膳奶贝配料 |
CN112106916A (zh) * | 2020-08-21 | 2020-12-22 | 广州白云山维一实业股份有限公司 | 一种复合益生菌固体饮料及其制备方法 |
CN114504109A (zh) * | 2020-11-16 | 2022-05-17 | 内蒙古伊利实业集团股份有限公司 | 一种含乳双歧杆菌与母乳低聚糖的组合物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101496575A (zh) * | 2008-01-28 | 2009-08-05 | 中国食品发酵工业研究院 | 一种含短肽和益生菌的特殊营养食品配方 |
WO2011088943A1 (en) * | 2010-01-22 | 2011-07-28 | Unilever Nv | Prebiotic use of water soluble soybean polysaccharide |
CN106473148A (zh) * | 2016-09-14 | 2017-03-08 | 吴卓蓉 | 一种复合益生菌组合物及其制备方法及应用 |
-
2019
- 2019-06-05 CN CN201910486048.0A patent/CN111466572A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101496575A (zh) * | 2008-01-28 | 2009-08-05 | 中国食品发酵工业研究院 | 一种含短肽和益生菌的特殊营养食品配方 |
WO2011088943A1 (en) * | 2010-01-22 | 2011-07-28 | Unilever Nv | Prebiotic use of water soluble soybean polysaccharide |
CN106473148A (zh) * | 2016-09-14 | 2017-03-08 | 吴卓蓉 | 一种复合益生菌组合物及其制备方法及应用 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112106916A (zh) * | 2020-08-21 | 2020-12-22 | 广州白云山维一实业股份有限公司 | 一种复合益生菌固体饮料及其制备方法 |
CN112006104A (zh) * | 2020-09-07 | 2020-12-01 | 内蒙古百瑞食品科技有限责任公司 | 一种轻膳奶贝配料 |
CN114504109A (zh) * | 2020-11-16 | 2022-05-17 | 内蒙古伊利实业集团股份有限公司 | 一种含乳双歧杆菌与母乳低聚糖的组合物及其应用 |
CN114504109B (zh) * | 2020-11-16 | 2024-02-09 | 内蒙古伊利实业集团股份有限公司 | 一种含乳双歧杆菌与母乳低聚糖的组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108991327A (zh) | 一种益生菌固体饮料及其制备方法 | |
US20100166721A1 (en) | Probotic compositions and uses thereof | |
US20110165127A1 (en) | Dairy-derived probiotic compositions and uses thereof | |
CN109123295A (zh) | 一种益生菌固体饮料及其制备方法 | |
CN107691955A (zh) | 益生菌固体饮料及其制备方法 | |
JP2000175615A (ja) | シンバイオティック機能性食品 | |
CN108740251A (zh) | 一种改善便秘的益生菌凝胶糖果及其制备方法 | |
CN111035014A (zh) | 一种益生菌制剂及其制备方法 | |
EP2396014A1 (en) | Lactobacillus rhamnosus ncc4007, a probiotic mixture and weight control | |
CN108823129B (zh) | 一种具有抵抗幽门螺旋杆菌作用的高活性益生菌固体饮料 | |
CN111466572A (zh) | 一种具有调节肠道功能的益生菌粉及其制备方法 | |
CN108477617A (zh) | 一种润肠通便的益生菌粉及其制备方法 | |
CN113826692A (zh) | 一种益生菌固体饮料及其制备方法 | |
CN105685970A (zh) | 一种全消化道改善的复合营养食品 | |
CN108770974A (zh) | 一种抗过敏的益生菌凝胶糖果及其制备方法 | |
CN108904546A (zh) | 一种对幽门螺旋杆菌有抑制、杀灭作用的益生菌组合制剂及其制备方法 | |
CN111557404A (zh) | 助消化益生菌固体饮料及其制备方法 | |
WO2020070087A1 (en) | Probiotic combination for treatment of inflammatory-related gastrointestinal disorders | |
CN111000247B (zh) | 一种复合益生菌粉的制备方法 | |
Khaneghah et al. | Probiotics and prebiotics as functional foods: state of the art | |
CN102300472A (zh) | 共生组合物及其制备方法 | |
CN112602778A (zh) | 含副干酪乳杆菌n1115的通便助眠奶粉及其制备方法 | |
Nagpal et al. | Probiotics, prebiotics and synbiotics: An introduction | |
CN111616369A (zh) | 一种含活性益生菌的营养代餐粉及其制备方法 | |
Janipour et al. | Effects of Partial Replacement of Sugar with Fig Syrup on the Survival of Bacillus coagulans and the Physicochemical Properties of Probiotic Ice Cream |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200731 |